Prostamax
Prostate bioregulator
Prostamax is a prostate peptide complex. The clinical literature people cite for it was generated on different products — Prostatilen and Vitaprost — and the honest thing to do with that is say so rather than borrow it.
Prostamax quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Prostate cytogen — course-based, of interest to older men. Prostate-directed, and the reason most men over fifty look at this set at all. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, baseline PSA before you start — without one, a later reading has nothing to compare against. Run it as an experiment you measure, not a protocol you trust.
What Prostamax actually is — and why that changes the mechanism
Prostamax is a prostate peptide complex — an extract. No sequence, no mass, no identified components. The mechanism written about it is the class story, imported: short peptides reaching the nucleus and modulating transcription in a tissue-specific way.
Tissue specificity is the claim doing all the work here, and it is the weakest one in the family. The entire commercial logic of this catalog is that a prostate extract acts on prostate, a liver extract on liver, and so on. For the defined peptides there is at least a mechanism-shaped argument — different sequences, different computed DNA preferences, different charges. For extracts there is nothing corresponding: no published composition, no comparison of one tissue complex against another in the same assay, and no demonstration that a prostate preparation does anything a thymus preparation does not. The organ-specificity claim is an assertion, and it is the assertion the whole product line depends on.
What would make it credible. One experiment: two tissue extracts, same assay, different outcomes. It has never been published, and until it is, tissue specificity in the extract range is marketing architecture rather than pharmacology.
What the primary literature on Prostamax actually says
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
The class's flagship human series, cited here for what it is: a study of thymus and pineal extracts in 266 elderly subjects. It is the evidence base for the bioregulator idea in general and says nothing about the prostate.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The tissue-specificity claim — that different short peptides act on different organ systems — which is the argument a prostate-specific product depends on.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
A calibration point from outside the school: when animal-derived preparations are reviewed independently, certainty of evidence comes back low to very low.
What is not here. Nothing is indexed under the trade name Prostamax. The prostate-extract clinical literature that does exist is published on Prostatilen and Vitaprost — same tissue class, different products, and the record does not transfer by similarity. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Prostamax evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Prostamax. Nothing is indexed under this trade name. The prostate-extract clinical record that does exist belongs to Prostatilen and Vitaprost, which are different preparations from the same tissue class — and a trial result does not transfer between products by similarity of ingredient any more than one statin's outcome trial transfers to another. Meanwhile the alternatives here are not weak: symptom scores and flow rates have been the standard endpoints in this field for thirty years.
What the data does support: nothing under this trade name. Nothing is indexed for Prostamax. It is worth being precise about what does exist nearby, because it is easy to mistake for evidence: the prostate-extract clinical literature that exists is published on Prostatilen and Vitaprost. Same tissue class, different products, different manufacturers — and because an extract has no verifiable identity, that record does not transfer by similarity. It is not this product's evidence.
The class's flagship human series — 266 elderly subjects over 6–8 years — studied thymus and pineal extracts. It says nothing about the prostate. The independent systematic review that graded this drug class covered cognitive disorders, and concluded “risk of bias was moderate to high, there was imprecision, and certainty of evidence was considered low to very low”. That is calibration on how this class fares under outside scrutiny, not evidence about prostate tissue.
The specific epistemic position: no trial, no animal study, no mechanism paper under this name; a related-but-different product line with some clinical literature; and an organ-specificity claim that has never been demonstrated for any extract. Absence of evidence — but a very thorough absence.
What is actually measured, and what is not. This prostate preparation has no trial, no animal study and no effect size under its own name. The nearby clinical literature belongs to Prostatilen and Vitaprost, which are separate products with separate manufacturing. Nobody has characterized how a prostate complex behaves pharmacokinetically. The half-life of its components is unrecorded. Its rate of clearance has never been established. Whether prostatic peptidase activity degrades it before it acts is untested. Delivery into prostate tissue has never been quantified. Its effect on androgen receptor signaling has never been examined. Transcription in prostate cells has never been read out under it. Nothing shows a component entering a prostatic nucleus. And no experiment anywhere shows a prostate extract doing something a thymus extract does not, which is the claim this whole product line rests on. The 2003 elderly series that anchors the class ran 6–8 years on other organs entirely.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Prostamax pharmacokinetics — how much of it actually gets in
Why there is no half-life. A mixture has as many clearance curves as components; “~30 min” in the quick facts is a figure without a study. Nothing has been characterized for this preparation in any species.
What can be reasoned. Short peptide components meet serum aminopeptidases and clear in minutes, which is compatible with the mechanism — a transcriptional signal outlasts the signal molecule — and which makes serum measurement useless. The interesting quantity is delivery to prostate tissue, and it has never been measured.
Route. Prostamax is injectable here. Subcutaneous injection is 100% bioavailable by definition and bypasses gastric acid, the brush-border peptidase layer and hepatic first-pass entirely. That matters because the named route by which an intact peptide crosses the gut wall is PEPT1, carrying di- and tripeptides, and a peptide complex is not a PEPT1 substrate — so an oral prostate complex would have no delivery mechanism behind it at all. The injectable form at least starts the argument in the bloodstream.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Prostamax to work
What would have to be true. The complex would have to contain active peptides — unpublished; they would have to reach prostate tissue after injection — unmeasured; act on prostate cells specifically rather than on any cell — undemonstrated for any extract; and change something a urologist would recognize. The prostate is unusually well served by validated measurement, which makes this one of the easiest claims in the cohort to test and one of the least tested.
A word on the last one before you run it: this is the compound in the cohort where self-testing carries real clinical weight, and a number moving in the wrong direction is a reason to see a doctor rather than to adjust a protocol.
- Prediction 1 — IPSS. should fall by a clinically meaningful margin, not just any margin, over 8–12 weeks. The International Prostate Symptom Score has an established minimum clinically important difference. A change smaller than that is noise wearing a number.
- Prediction 2 — Uroflowmetry. peak flow rate should rise if symptoms improve for a mechanical reason, same window. Separates a real obstructive change from a placebo effect on a questionnaire, which is the specific failure mode in this indication.
- Prediction 3 — PSA (Total + Free + % Free). should not move, over a course, measured before and 4–6 weeks after. A negative prediction that doubles as safety. Anything that moves PSA in either direction changes how the next screening result gets read, and a reader needs to know that before it happens rather than after.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Prostamax did to it — and that difference is the entire point of testing.
Prostamax versus the alternatives
Prostamax versus Libidon. Both are prostate peptide complexes from the same catalog, sold for overlapping goals, neither with anything indexed under its name. There is no published basis for preferring one over the other — not a trial, not a composition analysis, not a head-to-head. Any recommendation between them is preference dressed as expertise.
And against the credible alternatives, which is where this gets uncomfortable. Benign prostatic symptoms have well-characterized pharmacological treatments with large randomized trials, validated symptom scores and known adverse-effect profiles. Prostate cancer screening and management are entire evidence-based specialties. A peptide complex with no indexed literature is not competing with those on evidence, and the specific danger on this page — different from every other page in this cohort — is that urinary symptoms can be the presenting sign of something that needs diagnosing rather than supplementing. That is the honest comparison, and no vendor page makes it.
What you are actually buying when you buy Prostamax
Prostamax is an extract, not a molecule. A certificate of analysis can establish sterility, endotoxin, total protein and the absence of named contaminants. It cannot establish identity, because there is no formula to check against. Two clean certificates can describe two different mixtures.
Which is why the Prostatilen literature cannot be borrowed. If extracts had verifiable identity, a reader could ask whether this product matches the one in those studies. There is no assay that answers that question, so the answer is not “probably yes” — it is “unanswerable”. That is the practical consequence of buying a process rather than a molecule.
Extract rules, plus the one that matters for anything aimed at the prostate: know your PSA before you start. A product that shifts it either way, for any reason, muddies the only cheap screening tool there is.
Where to get Prostamax
Buy Prostamax at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Prostamax
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for prostate function and urinary flow. It is worth naming what it is competing with: saw palmetto has mixed but real trial data, and finasteride and tamsulosin have unambiguous approval-grade evidence for the same complaint.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A prostate-derived peptide preparation proposed to support prostate cell function and healthy volume.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- The real risk here is not the compound, it is the delay. Urinary symptoms in older men can indicate prostate cancer, and substituting an unevaluated peptide for a PSA test and an examination is where the actual harm sits.
What that tier rests on here. The tier above is class inference. Nothing is indexed under Prostamax; the prostate-extract clinical literature that exists belongs to Prostatilen and Vitaprost, which are different products.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Prostamax is one of the few products in this cohort with papers that name it — and every one of them is about a white blood cell. A PubTator3 search on 6 September 2026 returned three records carrying the trade name. Meskhi 2004, in Biofizika, reports its influence on heterochromatin in human lymphocytes in situ. Kiladze 2009 ran microcalorimetry on cultured human blood lymphocytes with copper, cadmium and Prostamax — a physical measurement of heat released, which is unusually hard evidence for this field. Khavinson 2004 is the parent result: short peptides and lymphocyte chromatin in senile subjects.
Read the tissue in each of those sentences. Lymphocyte. Lymphocyte. Lymphocyte. A prostate product whose entire named literature was produced by adding it to blood cells in a dish has not been studied in a prostate at all — and the reason is practical rather than sinister: lymphocytes are easy to get from an elderly donor and prostate tissue is not. It is still the gap, and no vendor states it.
A defined tetrapeptide sits underneath the trade name, and the papers do not connect them. Dzhokhadze 2012, from the same Tbilisi group, reports deheterochromatinization in aged chromatin under the oligopeptide Lys-Glu-Asp-Pro. That is a four-residue molecule with a mass a laboratory can confirm. The paper does not say which commercial product that sequence corresponds to, and neither does any vendor page — so the link between the peptide with a structure and the capsule with a label remains unstated in print.
The prostate-tissue evidence, such as it is. Borovets 2026 is a 2026 Urologiia report on prostate-derived complex peptide preparations and erectile function in chronic prostatitis; Ryzhak 2015 included prostate among seven calf-tissue extracts in organotypic culture; Khavinson 2001 is the original tissue-specificity claim. None of those three names this product, and none reports a PSA, a symptom score or an image.
Against the other prostate product on this site, the split is real. Three indexed papers carry the name Prostamax; a PubTator3 search for the A-16 prostate product on the same day returned one record, an ethnobotanical survey from the Democratic Republic of the Congo that matched on a string rather than on a subject. Neither product has a published composition, mass spectrum or assay, so they still cannot be told apart chemically — but on the count of papers that name them, they are not equivalent.
The delivery argument does not survive the oral route. Khavinson 2023 evaluated 26 ultrashort peptides against LAT and POT carriers by docking, with no transport measured in any living cell. An extract is not one of those 26 and has no structure to dock. Gastric acid, pancreatic proteases and the intestinal brush border each act on peptide bonds before absorption, and no paper in this class has measured what survives them.
Where it stops. Zero human endpoints under this name. No PSA, no symptom score, no imaging, in any published study.
What nobody has tested yet
The chromatogram nobody publishes. Two prostate peptide products, one instrument run, one overlay. It would either show two distinct preparations, which would justify two prices, or show one product under two names. Vendors in this market publish certificates covering sterility and total protein; none publishes a compositional profile, and until one does the difference between these products is an assertion.
An honest control arm exists and is unglamorous. A whey or casein hydrolysate is also a protease-digested animal protein preparation, costs a fraction as much, and would make an ideal comparator in any trial of an organ extract. No study in this class has ever used one. Until a peptide complex beats a generic protein hydrolysate on a real endpoint, the tissue of origin is a claim about manufacturing, not about biology.
Extrapolation, labeled as such. If the tissue-specificity doctrine is true, a prostate preparation should do something in prostate tissue that a liver preparation does not. That is a cross-over design in organotypic culture, the exact assay Ryzhak 2015 already uses, with the tissues deliberately mismatched. It is the single experiment that would either establish the central claim of this entire class or end it, and in fifty years nobody has published it in that form.
Sources read for this page
- Meskhi T. The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ. Biofizika 2004 [Russian] · PMID 15612551
- Kiladze M. Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax. Georgian Medical News 2009 · PMID 19359734
- Dzhokhadze TA. Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro). Georgian Medical News 2012 · PMID 23221144
- Khavinson VKh. Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine 2004 · PMID 15085253
- Borovets S Y. Effect of prostate-derived complex peptide preparations on erectile function in patients with chronic prostatitis. Urologiia 2026 [Russian] · PMID 42417303
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
Prostamax — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Prostamax — safety specifics for this compound
Specific to Prostamax: this is the one page in the cohort where the primary risk is not the compound. Urinary symptoms and prostate changes can be the first presentation of a condition that needs diagnosis, and anything taken to manage symptoms can delay that. The compound itself is a bovine-derived tissue extract with the protein-allergy and immunogenicity considerations that attach to any animal-source biologic, and no published safety study of its own. The named unknown is hormonal: a preparation from an androgen-responsive organ has never been examined for effects on the androgen receptor in anyone. PSA, free testosterone and DHT are the three that would have to be measured before and after to say anything at all, and in 0 published studies have they been.
Prostamax — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Prostamax moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Prostamax in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Prostamax
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Prostamax — frequently asked questions
Is Prostamax a peptide or an extract?
An extract — a peptide complex from prostate, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Prostamax?
Nothing is indexed under the trade name Prostamax. The prostate-extract clinical literature that does exist is published on Prostatilen and Vitaprost — same tissue class, different products, and the record does not transfer by similarity.
What should I measure if I run Prostamax?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Prostamax inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Prostamax is used for
Prostamax appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Prostamax is the dht & hair arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.